Craig Shapiro, MD
Nephrology · Jacksonville, FLNPI 1700824521
Payments from drug & device makers
Across 300 payments — averaging $2034.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$484K
- GSK$69K
- AstraZeneca$54K
- Amgen$404
- Vifor Pharma, Inc.$385
- Otsuka America Pharmaceutical, Inc.$372
- plus $2K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $484,431 |
| GSK | 9 | $68,664 |
| AstraZeneca | 134 | $54,446 |
| Amgen(2 entities) | 33 | $404 |
| Vifor Pharma, Inc. | 19 | $385 |
| Otsuka America Pharmaceutical, Inc. | 19 | $372 |
| Calliditas Therapeutics US Inc. | 17 | $342 |
| OPKO Pharmaceuticals, LLC | 8 | $135 |
| Mallinckrodt Hospital Products Inc. | 7 | $125 |
| Novartis | 5 | $117 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $107 |
| Intuitive Surgical | 1 | $94 |
| Ardelyx, Inc. | 3 | $88 |
| Fresenius USA Marketing, Inc. | 5 | $83 |
| Bayer | 4 | $79 |
| Travere Therapeutics, Inc. | 8 | $72 |
| Scpharmaceuticals Inc. | 3 | $68 |
| Aurinia Pharma U.S., Inc. | 3 | $63 |
| Novo Nordisk | 2 | $53 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Boehringer Ingelheim | 2 | $51 |
| Mallinckrodt Enterprises LLC | 2 | $47 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Boston Scientific | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Cormedix Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Akebia Therapeutics Inc | 1 | $16 |
| Bard Peripheral Vascular, Inc. | 1 | $13 |
How this compares
$610,439 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Jacksonville
- Fouad ChebibJacksonville$821K
- Nabeel AslamJacksonville$389K
- Ivan PorterJacksonville$342K
- Prasanth KrishJacksonville$340K
- Deborah PriceJacksonville$321K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.